Minimal Pharmacophoric Elements and Fragment Hopping, an Approach Directed at Molecular Diversity and Isozyme Selectivity. Design of Selective Neuronal Nitric Oxide Synthase Inhibitors
about
Role of zinc in isoform-selective inhibitor binding to neuronal nitric oxide synthaseAdvances in computationally modeling human oral bioavailabilityAnchored plasticity opens doors for selective inhibitor design in nitric oxide synthaseCrystal Structures of Constitutive Nitric Oxide Synthases in Complex with De Novo Designed Inhibitors †Unexpected Binding Modes of Nitric Oxide Synthase Inhibitors Effective in the Prevention of a Cerebral Palsy Phenotype in an Animal ModelStructure-based design, synthesis, and biological evaluation of lipophilic-tailed monocationic inhibitors of neuronal nitric oxide synthaseExploration of the Active Site of Neuronal Nitric Oxide Synthase by the Design and Synthesis of Pyrrolidinomethyl 2-Aminopyridine DerivativesSelective Monocationic Inhibitors of Neuronal Nitric Oxide Synthase. Binding Mode Insights from Molecular Dynamics SimulationsSimplified 2-Aminoquinoline-Based Scaffold for Potent and Selective Neuronal Nitric Oxide Synthase InhibitionThe Mobility of a Conserved Tyrosine Residue Controls Isoform-Dependent Enzyme–Inhibitor Interactions in Nitric Oxide SynthasesWhich neuroprotective agents are ready for bench to bedside translation in the newborn infant?Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain.Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthaseMechanistic studies of inactivation of inducible nitric oxide synthase by amidinesInvolvement of neuronal nitric oxide synthase in ongoing fetal brain injury following near-term rabbit hypoxia-ischemia.Neuronal nitric oxide synthase inhibition prevents cerebral palsy following hypoxia-ischemia in fetal rabbits: comparison between JI-8 and 7-nitroindazole.State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors.Acid-Facilitated Debenzylation of N-Boc, N-Benzyl Double Protected 2-Aminopyridinomethylpyrrolidine DerivativesTarget- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbersSelective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsyDiscovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping.Synthesis and enzymatic evaluation of 2- and 4-aminothiazole-based inhibitors of neuronal nitric oxide synthase.Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseases.L337H mutant of rat neuronal nitric oxide synthase resembles human neuronal nitric oxide synthase toward inhibitors.Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailabilityEffect of potential amine prodrugs of selective neuronal nitric oxide synthase inhibitors on blood-brain barrier penetration.Concise route to the chiral pyrrolidine core of selective inhibitors of neuronal nitric oxide.Recent advances toward improving the bioavailability of neuronal nitric oxide synthase inhibitors.Binding of small molecules at interface of protein-protein complex - A newer approach to rational drug design.Computational medicinal chemistry in fragment-based drug discovery: what, how and when.Fragment informatics and computational fragment-based drug design: an overview and update.De novo design: balancing novelty and confined chemical space.Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges.Nitric oxide synthase and structure-based inhibitor design.Fluorination Effects on NOS Inhibitory Activity of Pyrazoles Related to Curcumin.Structural basis for isoform-selective inhibition in nitric oxide synthase.Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.Fragment-based design of novel quinazolinon derivatives as human acrosin inhibitors.Insights into the structural determinants for selective inhibition of nitric oxide synthase isoforms
P2860
Q24635033-C4C6E5ED-E9AC-48D7-89EF-4D612C9C36F2Q27008316-762885A8-95AB-4D57-AA41-611D22ACA5BEQ27652490-3950A997-9C71-4E6B-851B-8F9C76D1652CQ27654198-2AF31FB9-6BFC-472B-8DD5-750CA8F05B78Q27660323-A93E130B-6E04-462B-9117-8F5B740718B7Q27663700-DE38F1FB-2C54-414A-93A8-34943C19F013Q27665170-074B32A8-9913-4B58-8D73-DD4F0EDA1B43Q27681378-19A5F412-D6F8-40AC-BAA2-23F96BE92236Q27681491-E8B48D30-3849-4571-A1DD-B9603562C39BQ27684931-A08C86EC-C137-4137-B0F5-F45F52906B0EQ33723452-84ADA41F-B6BF-4CF3-A247-E9F91300C401Q34067176-847CCD6A-AD1D-4B88-A43C-7524BEC5C966Q35087382-D621C02E-920B-420F-A434-8411A4753F3FQ35540305-C2E1E855-6D1B-4303-814F-1BACFF0DC795Q35576390-B9F0E608-9590-4EAD-8C9C-46E5B6448FAAQ35576401-94F9DB8B-187B-4CEC-BF96-5B7F93C5637CQ35738960-4118A14F-2087-4EB6-860E-9637F620F897Q35982641-F21B1135-5066-47CB-BFB4-DEA28CA2E0ACQ36799584-2142E8A4-0F3B-491B-849F-0B153F0C07ABQ37135549-52FE94EB-C22E-4DA2-BFD7-06C404EF9FC1Q37147032-37444421-282B-4995-BD22-8931921E48A3Q37253516-BE8BF503-742D-4BF8-9918-28180C771A0EQ37372675-A0BED283-7FA7-42A3-9C4E-C422718A7259Q37379442-9DCFF175-EAB3-49BF-A33B-3ECD01B84792Q37416111-2673FC7C-1687-4D3B-9F34-EF2DA99CB437Q37416804-E74E73C6-F337-4F9C-B102-8A928349D03AQ37439981-17D8453C-3965-47B5-9AEB-E37278C77136Q37556774-6B4CFEC7-4355-45A9-A846-A3F019B5AC8BQ37610874-0DF9AD3D-0A16-467B-8147-E382F6AEAA17Q37856296-AA3A1A67-A703-4848-8F6E-10853FDE2CA9Q37995087-059887AE-D017-4F86-A910-AAFB5E586CFCQ38029143-75EDCB26-ADA8-4585-9F0D-DD19AEFDC5F4Q38044374-D643EB98-0257-4FDC-9D30-512EBD0FC51BQ39021613-73AF444F-7606-4A86-B496-732E60B605B9Q40569105-706E2D89-4B73-45BB-9BE0-2165AC5B83B1Q42146949-ED5047DC-C648-460E-98A5-BA150C9DD125Q47137233-48498815-48FD-47FC-9991-E09DC19041D5Q49346285-61943347-6961-45D1-8D71-68CCB4BEE13AQ51837156-527A4678-36A8-450F-9F3B-AC96621D7ED5Q57990988-207A162D-7419-42F1-8C68-06EDF3DE7B1C
P2860
Minimal Pharmacophoric Elements and Fragment Hopping, an Approach Directed at Molecular Diversity and Isozyme Selectivity. Design of Selective Neuronal Nitric Oxide Synthase Inhibitors
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Minimal Pharmacophoric Element ...... tric Oxide Synthase Inhibitors
@ast
Minimal Pharmacophoric Element ...... tric Oxide Synthase Inhibitors
@en
Minimal Pharmacophoric Element ...... tric Oxide Synthase Inhibitors
@nl
type
label
Minimal Pharmacophoric Element ...... tric Oxide Synthase Inhibitors
@ast
Minimal Pharmacophoric Element ...... tric Oxide Synthase Inhibitors
@en
Minimal Pharmacophoric Element ...... tric Oxide Synthase Inhibitors
@nl
prefLabel
Minimal Pharmacophoric Element ...... tric Oxide Synthase Inhibitors
@ast
Minimal Pharmacophoric Element ...... tric Oxide Synthase Inhibitors
@en
Minimal Pharmacophoric Element ...... tric Oxide Synthase Inhibitors
@nl
P2093
P2860
P356
P1476
Minimal Pharmacophoric Element ...... tric Oxide Synthase Inhibitors
@en
P2093
Benjamin Z Stanton
Huiying Li
Jotaro Igarashi
Linda J Roman
Pavel Martásek
Richard B Silverman
Thomas L Poulos
P2860
P304
P356
10.1021/JA0772041
P407
P577
2008-03-26T00:00:00Z